Vectus Biosystems

Vectus Biosystems Limited is an emerging biotechnology company located in Sydney, Australia. The company has developed and patented a number of novel compounds for the treatment of chronic fibrotic diseases, including fibrosis of the heart, kidneys, liver, and lungs. Its candidate drug, VB0004, aims to inhibit and reverse the loss of functional tissue caused by fibrosis and is currently in human trials.